Kasvu’s €30M series A to take novel antidepressant into the clinic

Finnish newco Kasvu Therapeutics has raised €30 million (US$34.4 million) in a series A financing to take forward novel small molecules that have the antidepressant benefits of psychedelic drugs, but none of the hallucinogenic effects.